Basics - Deferment- Individuals - Tissues Regulated - Infections - Potential Impact - Global Policies - Safety - Recommendations
*Click on Underlined Sections to Jump to the Topic*
**Topics not in bold are currently being researched and prepared for release**
*Click on Underlined Sections to Jump to the Topic*
**Topics not in bold are currently being researched and prepared for release**
Start Here (Basics):
Basics & Breakdown Overview
|
|
|
FDA & CTGTAC
|
Organs Vs Tissues
|
|
|
The 12 TissuesThe FDA's 2007 guidance: "Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)" regulates 12 tissues explicitly. These are:
|
The History
|
|
|
CBER 2023 Agenda
|
A Tale of 2 Donors
|
|
|
Title 21- Code of Federal Regulations (CFR)
|
The Deferral Policy
|
Donor Screening
|
Donor Assessment
|
|
The Individuals
|
Liam Dee & Canada
|
AJ Betts & The Impact of the Ban
|
|
|
TreVaughn Roach-Carter
|
Tissues Impacted by the Ban
|
Cornea Donation
|
Sclera Donation
|
|
|
Skin Donation
|
Heart Valve Donation
|
|
|
Dura Mater Donation
|
Bone Donation
|
|
|
Tendon Donation
|
Ligament Breakdown
|
|
|
Cartilage Donation
|
Oocyte (Egg) Donation
|
|
|
Sperm Donation
|
Hematopoietic Stem Cell Donation
|
|
|
Additional Tissues Not Listed in the 2007 Policy
|
The Infections
|
Human Immunodeficiency Virus
|
Hepatitis B
|
|
|
Testing of All Donors
|
Testing of Reproductive Tissues
|
|
|
Testing of Leukocyte-Rich Tissues
|
Other Relevant Infections
|
|
Global Policies
|
United Kingdom
|